RECRUITING

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

Talk to us

Conditions

Prostate CancerProgressive Prostate Cancer[18F]-Fluoro-2-Deoxy-D-Glucose[18F] Dihydro-TestosteronePet ImagingPet scan00-095

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.

Official Title

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

Quick Facts

Study Start:2003-02
Study Completion:2026-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00588185

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients with histologically confirmed prostate cancer.
  2. * Progressive disease manifest by either:
  3. * Imaging modalities:
  4. * Bone Imaging: New osseous lesions on bone imaging (bone scintigraphy or NaF PET scan) and/or MRI or CT: An increase in measurable soft tissue disease, or the appearance of new sites of disease. Or
  5. * Biochemical progression: A minimum of three rising PSA values from a baseline that are obtained 1 week or more apart, or 2 measurements 2 or more weeks apart.
  6. * Visible lesions by either CT, bone imaging, or MRI consistent with disease.
  7. * Informed consent.
  1. * Previous anaphylactic reaction to either FDHT or FDG
  2. * Hepatic: Bilirubin \> 1.5 x upper limit of normal (ULN), AST/ALT \>2.5 x ULN, albumin \< 2 g/dl, and GGT \> 2.5 x ULN IF Alkaline phosphatase \> 2.5 x ULN
  3. * Renal: Creatinine \>1.5 x ULN or creatinine clearance \< 60 mL/min

Contacts and Locations

Study Contact

Michael Morris, M.D., PH.D.
CONTACT
646-422-4469

Principal Investigator

Michael Morris, M.D., Ph.D.
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Basking Ridge (Consent Only)
Basking Ridge, New Jersey, 07920
United States
Memorial Sloan Kettering Monmouth (Consent only)
Middletown, New Jersey, 07748
United States
Memorial Sloan Kettering Bergen (Consent Only)
Montvale, New Jersey, 07645
United States
Memorial Sloan Kettering Commack (Consent only)
Commack, New York, 11725
United States
Memorial Sloan Kettering Westchester (Consent only)
Harrison, New York, 10604
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States
Memorial Sloan Kettering Nassau (Consent Only)
Uniondale, New York, 11553
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Michael Morris, M.D., Ph.D., PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2003-02
Study Completion Date2026-02

Study Record Updates

Study Start Date2003-02
Study Completion Date2026-02

Terms related to this study

Keywords Provided by Researchers

  • Progressive Prostate Cancer
  • [18F]-Fluoro-2-Deoxy-D-Glucose
  • [18F] Dihydro-Testosterone
  • Pet Imaging
  • Pet scan
  • 00-095

Additional Relevant MeSH Terms

  • Prostate Cancer